Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00856388 · ClinicalTrials.gov registry record · NA
Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders
A NA study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 62
- Enrollment target
NCT00856388 is a NA study that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 62 participants.
The verdict
NCT00856388, a NA study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 62 participants
- Enrollment target
Study Summary
This clinical trial is studying how well giving fludarabine phosphate and melphalan together with total-body irradiation followed by donor stem cell transplant works in treating patients with hematologic cancer or bone marrow failure disorders. Giving low doses of chemotherapy and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells or abnormal cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer or abnormal cells (graft-versus-tumor effect)
Interventions
- DRUG fludarabine phosphate
- DRUG melphalan
- PROCEDURE allogeneic hematopoietic stem cell transplantation
- BIOLOGICAL anti-thymocyte globulin
- RADIATION total-body irradiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2009-01-14 |
| Est. Completion | 2019-03-13 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00856388
The ClinicalTrials.gov registry entry for NCT00856388 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which fludarabine phosphate is the first listed.
NCT00856388 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00856388 about?
NCT00856388 is a clinical study titled "Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders". This clinical trial is studying how well giving fludarabine phosphate and melphalan together with total-body irradiation followed by donor stem cell transplant works in treating patients with hematologic cancer or bone marrow failure disorders. Giving low doses of chemotherapy and total-body irradia...
What is the current status of trial NCT00856388?
This trial is currently completed. It is a NA study. The enrollment target is 62 participants. The study started on 2009-01-14. Estimated completion is 2019-03-13.
What interventions are being tested in trial NCT00856388?
The interventions under investigation include: fludarabine phosphate (DRUG), melphalan (DRUG), allogeneic hematopoietic stem cell transplantation (PROCEDURE), anti-thymocyte globulin (BIOLOGICAL), total-body irradiation (RADIATION).
Who is sponsoring clinical trial NCT00856388?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.